The biomanufacturing sector is experiencing a digitalisation transformation that is aligned with Industry 4.0. Frost & Sullivan’s says digital tools applied across processes, monitoring, analytics, and operations have accelerated biomanufacturing with a data-driven approach.
Some of the most difficult challenges are scalability and reproducibility, particularly in the production of biologics and cell and gene therapies. However, digitalisation enables a long-term, effective, cost-effective, and error-free biomanufacturing system.
“Digitalisation improves the entire value chain of manufacturing biologics, competitive generic therapy (CGT) products, and vaccines,” said Neeraja Vettekudath, healthcare research analyst at Frost & Sullivan. “Automated processes, remote monitoring, and digital supply chains accelerate biomanufacturing rates of biopharmaceuticals.”
She added that digitalisation deploys advanced sensors, artificial intelligence (AI)/machine learning (ML), and blockchain to create platforms.
“It builds seamless biomanufacturing systems where information is passed from one stage to the next. This increases efficiency, creating growth opportunities for digital biomanufacturing solution providers, enablers, and adopters.”
Neeraja Vettekudath
Recommendations for market participants
Invest in building digital twin models for predictive and data-driven biomanufacturing decisions.
Make an initial investment in digital tools that streamline processes.
Incorporate advanced software or AI tools to make sense of bioprocess data and accelerate the advancement toward developing robust and high-power processing systems that can use this data.
